AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rising	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	206006	ANDA	Rising Pharma Holdings, Inc.	57237-001-14	14 BLISTER PACK in 1 CARTON (57237-001-14) / 1 KIT in 1 BLISTER PACK (57237-001-01)	2016-10-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The pharmaceutical industry continuously relies on a global network of suppliers for essential active pharmaceutical ingredients (APIs) and finished medicinal products. Key drugs such as Amoxicillin, Clarithromycin, and Lansoprazole are widely used, necessitating robust supply chains to ensure consistent manufacturing and access. This article explores the primary suppliers and manufacturing sources for these drugs, examining their global distribution, manufacturing capacities, and implications for pharmaceutical stakeholders.

Amoxicillin Suppliers

Overview:
Amoxicillin, a broad-spectrum penicillin antibiotic, ranks among the most prescribed antibiotics worldwide. Its supply chain is characterized by multiple international manufacturers, predominantly in India, China, and Europe.

Major Suppliers:

Sino-American Tianjishen Pharmaceutical Co., Ltd. (China): Known for large-scale API production for antibiotics, including Amoxicillin. The company benefits from China's expanding pharmaceutical manufacturing infrastructure.
Hubei Huixin Pharmaceutical Co., Ltd. (China): A key API manufacturer specializing in penicillin derivatives, including Amoxicillin, with growing export volumes driven by lower manufacturing costs.
CSPC Pharmaceutical Group Ltd. (China): A leading pharmaceutical company with significant API manufacturing capacity, supplying both domestic and international markets.
Aurobindo Pharma Ltd. (India): One of the largest generic drug manufacturers globally, with substantial API production capabilities for Amoxicillin, exporting across North America, Europe, and Asia.
Teva Pharmaceutical Industries Ltd. (Israel): Engages in API sourcing for proprietary formulations, often partnering with Asian manufacturers to meet global demand.

Supply Dynamics and Risks:
India and China dominate API production due to cost efficiency and manufacturing scale. However, geopolitical tensions, regulatory shifts, and supply chain disruptions pose risks to the stability of Amoxicillin supplies. Recent geopolitical conflicts and the COVID-19 pandemic increased vigilance on supply chain resilience.

Clarithromycin Suppliers

Overview:
Clarithromycin, a macrolide antibiotic, is more complex to manufacture than Amoxicillin, requiring specialized fermentation processes. The supply chain is comparatively concentrated but strategically distributed.

Major Suppliers:

Shenzhen Ljl Pharmaceutical Co., Ltd. (China): A noteworthy producer for Clarithromycin APIs, leveraging fermentation expertise and offering competitive pricing.
Jiangsu Huangshan Pharmaceutical Co., Ltd. (China): Offers Clarithromycin and related macrolides, with extensive fermentation facilities conforming to international standards.
AbbVie Inc. (USA): Originally developed Clarithromycin, with some manufacturing retained in developed markets; however, much API production is outsourced to Chinese and Indian manufacturers.
Teva Pharmaceuticals (Israel): As with Amoxicillin, Teva sources Clarithromycin APIs from Asian manufacturers for global distribution.

Supply Considerations:
Clarithromycin APIs originate predominantly from Chinese and Indian API manufacturers due to fermentation technologies requiring specialized expertise. Manufacturing capacity has expanded in the past decade, but demand surges remain a concern, especially amid geopolitical uncertainties.

Lansoprazole Suppliers

Overview:
Lansoprazole, a proton pump inhibitor (PPI), is synthesized via complex chemical processes, and production capacity has been established predominantly in India, China, and Western Europe.

Major Suppliers:

Sun Pharmaceutical Industries Ltd. (India): A prominent producer of Lansoprazole with large-scale manufacturing infrastructure, supplying both the domestic Indian market and exports globally.
Cadila Pharmaceuticals (India): Engages in API manufacturing for Lansoprazole, benefiting from cost-effective Indian pharmaceutical manufacturing standards.
Mochida Pharmaceutical Co., Ltd. (Japan): Supplies finished formulations and APIs, especially within the Asian markets, with high regulatory standards.
Sandoz (Novartis) (Switzerland): Produces Lansoprazole as a generic, with manufacturing facilities in Europe supplying global markets.

Supply Chain Outlook:
Lansoprazole APIs are manufactured mainly in India and China owing to the cost advantages, with Western corporations maintaining quality controls and regulatory approvals. The supply chain remains resilient but is susceptible to raw material shortages and geopolitical tensions.

Global Manufacturing and Distribution Trends

Primary Manufacturing Regions: China and India dominate API production for all three drugs due to cost efficiencies, regulatory frameworks, and infrastructure development.
Quality Assurance: International regulatory agencies, including the FDA (U.S.), EMA (Europe), and equivalents in Asia, impose strict standards, requiring suppliers to adhere to Good Manufacturing Practices (GMP).
Supply Chain Risks: Geopolitical tensions, export restrictions, logistical disruptions, and quality compliance pose threats to uninterrupted supply. Recent events, such as the COVID-19 pandemic, have accentuated vulnerabilities in the supply chain for these essential medicines.

Implications for Pharmaceutical Stakeholders

Manufacturers: Diversification of supplier bases is critical to mitigate risks associated with geopolitical or regulatory disruptions. Strategic inventory management and backup suppliers are increasingly vital.
Regulators: Ensuring API quality and traceability remains paramount, especially for generics sourced from low-cost manufacturing hubs.
Healthcare Providers: Reliance on a concentrated supply can impact pricing and availability; thus, procurement strategies should prioritize supply chain resilience.

Key Takeaways

The supply of Amoxicillin, Clarithromycin, and Lansoprazole primarily relies on Chinese and Indian API manufacturers, with Western firms focusing on quality control and final formulation manufacturing.
Supply chain risks, including geopolitical tensions, raw material shortages, and regulatory compliance, necessitate diversification and strategic sourcing.
Growing regulatory scrutiny underscores the importance of quality assurance and traceability in global API supply chains.
The pharmaceutical industry must adapt by fostering resilient, diversified supply networks and leveraging regional manufacturing capabilities.
Continued investment in manufacturing in high-regulation environments can enhance supply stability for critical antibiotics and PPIs.

FAQs

1. Are Chinese and Indian suppliers of Amoxicillin and Clarithromycin considered reliable?
Yes, numerous Chinese and Indian API manufacturers maintain GMP standards and supply large volumes globally. However, due diligence and regulatory audits are essential to ensure quality and compliance.

2. How can supply chain disruptions impact drug availability?
Disruptions can lead to shortages, increased costs, and reliance on alternative suppliers or formulations, potentially impacting patient access and treatment outcomes.

3. What steps are industry players taking to mitigate supply chain risks?
Strategies include supplier diversification, increasing inventory buffer stocks, establishing regional manufacturing hubs, and enhancing regulatory oversight of suppliers.

4. Are there bioequivalent or alternative drugs that can replace Amoxicillin, Clarithromycin, or Lansoprazole in case of shortages?
Yes, alternative antibiotics or PPIs may be used, but substitution depends on clinical suitability and regulatory approval, emphasizing the importance of supply chain stability for these specific drugs.

5. What role do regulatory authorities play in ensuring supply chain security?
Authorities enforce GMP standards, conduct inspections, approve manufacturing facilities, and monitor supply chain risks to ensure the safety, quality, and availability of pharmaceuticals.

References

[1] U.S. Food and Drug Administration (FDA). "Drug Shortages." FDA.gov.
[2] MarketWatch. "Global API Market Outlook."
[3] Pharmaceutical Technology. "The state of global API manufacturing."
[4] Statista. "Leading global pharmaceutical API suppliers."
[5] World Health Organization. “Assessment of API Manufacturing Practices.”

Suppliers and packagers for generic pharmaceutical drug: AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE